Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes

Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506). To see the French language version of this discussion, click here.

Related Videos

CNS Cancers

Julie R. Park, MD, on Neuroblastoma: Results of a Children’s Oncology Group Study

Julie R. Park, MD, of Seattle Children’s Hospital, discusses findings from this phase III trial of tandem myeloablative autologous stem cell transplant using peripheral blood stem cel...

Breast Cancer

Hope S. Rugo, MD, on HER2+ Breast Cancer: Findings on a Trastuzumab Biosimilar

Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III study results on a new possible alternative to trastuzumab for HER2-positive metastatic breast ca...

Clifford A. Hudis, MD, Allen S. Lichter, MD, and Richard L. Schilsky, MD, on Passing the Torch

Richard L. Schilsky, MD (right), Chief Medical Officer of ASCO, talks with incoming ASCO CEO Clifford A. Hudis, MD (left) and outgoing CEO

Gastrointestinal Cancer

Gastroesophageal Cancer

Salah-Eddin Al-Batran, MD, on Gastric and GEJ Adenocarcinoma: Results From the FAST Trial

Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses findings from this international phase II study of epirubicin, oxaliplatin, an...

Multiple Myeloma

Michele Cavo, MD, on Multiple Myeloma: Results From a European Myeloma Network Trial

Michele Cavo, MD, of the Seràgnoli Institute of Hematology, Bologna University School of Medicine, discusses results from this phase III study of upfront autologous stem cell transpla...